Prevalence of gyrA and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different Fluoroquinolones | ||||
| Sohag Medical Journal | ||||
| Article 38, Volume 22, Issue 1, January 2018, Page 229-241 PDF (115.65 K) | ||||
| DOI: 10.21608/smj.2018.41679 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Laila M Yousef1; Ghada A Ismael2; Ashraf k Mohammed3; Mohamed H Mahmoud3 | ||||
| 1Department of Clinical and Chemical pathology, Faculty of Medicine, Sohag University. | ||||
| 2Department of Clinical Pathology, Faculty of Medicine, Ain Shams University. | ||||
| 3Department of Clinical Pathology, Faculty of Medicine, Sohag University. | ||||
| Abstract | ||||
| Introduction: Streptococcus pneumoniae is a major Gram-positive pathogen responsible for pneumonia, bactermia, otitis media, and meningitis leading to considerable morbidity and mortality among children and elderly individuals. The primary goals of antibiotic treatment of respiratory tract infections are clinical efficacy of treatment, pathogen eradication, and prevention of resistance development. Resistance to fluoroquinolones in S. pneumoniae arises in a stepwise fashion and results from alterations in the target binding site due to the acquisition of spontaneous mutations in the quinolone resistance-determining regions (QRDRs) of the topoisomerase IV and DNA gyrase genes. Although mutations usually occur in the QRDRs of parC and gyrA, a role for mutations in the parE subunit in low-level resistance has been reported. Aim of the work: The aim of this study was to determine the prevalence of fluoroquinolone resistance Streptococcus pneumoniae (FQRSP) and to examine the genetic relatedness of pneumococcal isolates with parE and gyrA genes mutations in different specimens in Sohag University Hospital. Patients and Methods: This study was prospectively conducted over a period of 24 months between October 2015 and September 2017, at Sohag university hospital. During the study period, 78 patients hospitalized for a syndrome consistent with a diagnosis of community acquired pneumonia (CAP ) included in this study with a mean age of 34.5 years (range, 2 to 67), 60% of whom were males. A CAP syndrome was defined as a newly recognized pulmonary infiltrate together with 2 of the following findings: subjective fever or documented temperature 37.4 °C, increased cough, sputum production, or shortness of breath, pleuritic chest pain, confusion, rales, leukocytosis, (according to age) (1). Patients who had taken antibiotic treatment within 3 days prior to initial visit were excluded from this study. Results: Our study illustrate the role of mutation in the gyrA&parE genes and the effect of mutations in the both genes in fluoroquinolone resistance among S. pneumoniae isolates. Conclusion: The present study provide an opportunity to view the predominant mutations conferring reduced susceptibility to FQs in clinical pneumococcal isolates. There is a strong relationship between these mutations and decrese susceptibility to the most fameous FQs to some extent, although this varies between strains and for each drug. | ||||
| Keywords | ||||
| gyrA; ParE; Streptococcus pneumonia; Fluoroquinolones | ||||
|
Supplementary Files
|
||||
| References | ||||
|
1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic fluoroquinolones, such as sparfloxacin or gatifloxacin(25, 26), but are rarely reported for clinical isolates. This may reflect the relatively recent use of newer fluoroquinolones that select for gyrA mutations first. Also, isolates with a single mutation in gyrA may be overlooked if the MIC of the fluoroquinolone agent(s) used to screen for resistance is unchanged or only modestlyincreased. although this varies between strains and for eachdrug. in (QRDRs) in S. pneumonia isolates and resistance toFluoroquinlones. The maintenance of such surveillance is valuable in the preparation of future therapy guidelines and could lead to new therapeutic strategies for FQ-resistant S.Pneumoniae. Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases: anofficialpublication of the Infectious Diseases Society of America. 2007;44 Suppl 2:S27-72.
2. Patel SN, McGeer A,Melano R, Tyrrell GJ, Green K, Pillai DR, et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrobial agents and chemotherapy.2011;55(8):3703-8.
3. Morrissey I, Farrell DJ, Bakker S, Buckridge S, Felmingham D. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or - susceptible Streptococcus pneumoniae from Hong Kong. Antimicrobial agents and chemotherapy.2003;47(4):1433-5.
4. de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Perez-Trallero E, Linares J, et al. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerging infectious diseases. 2004;10(10):1751-9.
5. Fisher LM, Gould KA, Pan XS, Patel S, Heaton VJ. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy. 2003;52(2):312-3; author reply3-4.
6. Andersson MI, MacGowan AP. Development of the quinolones. The Journal of antimicrobial chemotherapy. 2003;51 Suppl 1:1-11.
7. Collins MD, Hutson RA, Hoyles L, Falsen E, Nikolaitchouk N, Foster G. Streptococcus ovis sp. nov., isolated from sheep. International journal of systematic and evolutionary microbiology. 2001;51(Pt3):1147-50.
8. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrobial agents a chemotherapy. 2003;47(6):1867-74.
9. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001;293(5529):498-506.
10. Hoskins J, Alborn WE, Jr., Arnold J, Blaszczak LC, Burgett S, DeHoff BS, et al. Genome of the bacterium Streptococcus pneumoniae strain R6. Journal of bacteriology. 2001;183(19):5709-17.
11. Kargar M, MoeinJahromi F, Doosti A, Handali S. Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction- Restriction Fragment Length Polymorphism Method. Osong public health and research perspectives. 2014;5(5):245-50.
12. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, et al. Fluoroquinoloneresistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrobial agents and chemotherapy. 2000;44(11):3049-54.
13. Broskey J, Coleman K, Gwynn MN, McCloskey L, Traini C, Voelker L, et al. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. The Journal of antimicrobial chemotherapy. 2000;45 Suppl1:95-9.
14. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrobial agents and chemotherapy.2002;46(3):680-8.
15. Korzheva N, Davies TA, Goldschmidt R. Novel Ser79Leu and Ser81Ile substitutions in thequinolone
resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrasesubunits fromb recent fluoroquinolone-resistant Streptococcuspneumoniaeclinical isolates.Antimicrobial agents and chemotherapy.2005;49(6):2479-86.
16. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrobial agents and chemotherapy.2002;46(1):119-24.
17. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerging infectious diseases.2003;9(7):833-7.
18. Patel SN, Melano R, McGeer A, Green K, Low DE. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada. Annals of clinical microbiology and antimicrobials.2010;9:3.
19. Kawamura-Sato K, Hasegawa T, Torii K, Ito H, Ohta M. Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. Current microbiology.2005;51(1):27-30. Credito K, Kosowska-Shick K, McGhee P, Pankuch GA, Appelbaum PC. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci. Antimicrobial agents and chemotherapy.2010;54(2):673-7.
20. Ip M, Chau SS, Chi F, Qi A, Lai RW. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single- strandn conformational polymorphism. Journal of clinical microbiology.2006;44(3):970-5.
21. Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, et al. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.2005;11(9):750-8.
22. Brino L, Urzhumtsev A, Mousli M, Bronner C, Mitschler A, Oudet P, et al. Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center. The Journal of biological chemistry. 2000;275(13):9468-75.
23. Fass D, Bogden CE, Berger JM. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nature structural biology.1999;6(4):322-6.
24. Fukuda H, HiramatsuK. Primary targets of fluoroquinolones in Streptococcuspneumoniae. Antimicrobialagents and chemotherapy.1999;43(2):41
25. Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrobial agents and chemotherapy. 1997;41(2):471-4.
| ||||
|
Statistics Article View: 139 PDF Download: 149 |
||||
